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Caroline Demily1* and Frédéric Sedel2Abstract
Detecting psychiatric disorders of secondary origin is a crucial concern for the psychiatrist. But how can this reliably be
done among a large number of conditions, most of which have a very low prevalence? Metabolic screening undertaken
in a population of subjects with psychosis demonstrated the presence of treatable metabolic disorders in a significant
number of cases. The nature of the symptoms that should alert the clinician is also a fundamental issue and is not
limited to psychosis. Hereditary metabolic disorders (HMD) are a rare but important cause of psychiatric disorders in
adolescents and adults, the signs of which may remain isolated for years before other more specific organic signs
appear. HMDs that present purely with psychiatric symptoms are very difficult to diagnose due to low awareness of
these rare diseases among psychiatrists. However, it is important to identify HMDs in order to refer patients to specialist
centres for appropriate management, disease-specific treatment and possible prevention of irreversible physical and
neurological complications. Genetic counselling can also be provided. This review focuses on three HMD categories:
acute, treatable HMDs (urea cycle abnormalities, remethylation disorders, acute intermittent porphyria); chronic, treatable
HMDs (Wilson’s disease, Niemann-Pick disease type C, homocystinuria due to cystathionine beta-synthase deficiency,
cerebrotendinous xanthomatosis); and chronic HMDs that are difficult to treat (lysosomal storage diseases, X-linked
adrenoleukodystrophy, creatine deficiency syndrome). We also propose an algorithm for the diagnosis of HMDs in
patients with psychiatric symptoms.
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Detecting psychiatric disorders of secondary origin is a
crucial concern for the psychiatrist. But how can this reli-
ably be done among a large number of conditions, most
of which have a very low prevalence? A study performed
some time ago [1] involving a sample of 658 patients who
had a psychiatric consultation with a complete clinical
evaluation and full investigations showed that 9.1% of
these patients had a physical condition that presented with
psychiatric symptoms. Moreover, such conditions are be-
lieved to be the leading cause of psychiatric disorders in
the elderly. Metabolic screening undertaken in subjects
with psychosis demonstrated the presence of treatable
metabolic disorders in a significant number of cases; there
were 15 cases out of 268 patients [2]. One in 20 patients
might therefore be affected.* Correspondence: caroline.demily@ch-le-vinatier.fr
1Centre for the Detection and Management of Psychiatric Disorders of
Genetic Origin, Hospital le Vinatier and UMR 5229 (CNRS and Lyon
University), 95 Bld Pinel, Bron, Cedex 69677, France
Full list of author information is available at the end of the article
© 2014 Demily and Sedel; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.The nature of the symptoms that should alert clini-
cians is also a fundamental issue. A study in adolescents
with clinical criteria of catatonia found the presence of a
general medical condition in 22% of cases and the pres-
ence of a neurodevelopmental disorder in 31% [3].
Several large aetiological groups have been identified
among which hereditary metabolic disorders (HMD) are a
rare but important cause of psychiatric disorders in adoles-
cents and adults [4]. For example, in 1985, Tishler et al.
examined 3,867 psychiatric inpatients in the United States
to determine the incidence of acute intermittent porphyria
(AIP) and found the rate to be 20 times greater than that
of the general population. A retrospective analysis of pa-
tients with various HMDs shows that the psychiatric signs
may remain isolated for years before other more specific
organic signs appear [5]. HMDs that present purely with
psychiatric symptoms are very difficult to diagnose because
psychiatrists often do not recognise these rare diseases.
However, it is important to identify HMDs in order tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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– refer patients to a referral centre for appropriate
management
– initiate specific treatment and prevent the
occurrence of irreversible physical and neurological
complications—the prognosis of HMDs has been
revolutionised by new therapeutic approaches
– provide genetic counselling to the patient and the
whole family.
Treatments are available for some HMDs, which we
focus on in this article (Table 1). Metabolic decompensa-
tion may be prevented and simple; appropriate advice
may be provided. In most cases in adults, psychiatric
disorders, not limited to psychosis, are the manifesta-
tions that point to the presence of HMDs. The diagnosis
of the disease ‘at the psychiatric stage’ corresponds to a
relatively early phase, and thus, the treatment can have
maximum efficacy. If the disease is not picked up at the
psychiatric stage, irreversible lesions occur secondarily.
It is therefore essential that psychiatrists are aware of
these for the differential diagnosis and that opportunities
to help the patient are not missed [6,7].Table 1 Psychiatric manifestations of treatable hereditary me
cases from the literature)
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HMD hereditary metabolic disorders.HMDs can be classified into three categories:
– acute, treatable HMDs
– chronic, treatable HMDs
– chronic HMDs that are difficult to treat.
Acute, treatable HMDs
This group includes urea cycle abnormalities, remethyla-
tion disorders and the porphyrias. The acute manifesta-
tions often have an element of confusion (sometimes
poorly detected and considered as an acute psychotic dis-
order) and, in certain cases, have a rhythmicity to them.
Urea cycle abnormalities
The urea cycle is the metabolic pathway in the liver that
eliminates excess endogenous and exogenous nitrogen
through detoxification of ammonia into urea. The dis-
eases of the urea cycle include a group of six distinct en-
zyme deficiencies of genetic origin, all of which result in
dysfunction of the urea cycle and a rise in the serum
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while the other deficiencies have an autosomal recessive
pattern of inheritance.
Hereditary urea cycle deficiencies may present at any
age (prevalence 1/10,000) [8]. In addition to forms that
present in the neonatal period and in young children,
there are forms with a late onset discovered in adoles-
cents or young adults. These diseases may cause confu-
sion, behavioural disorders or hallucinations that may
suggest an atypical form of depression [9], an acute
psychotic disorder or even resemble schizophrenia [10].
Patients often have protein intolerance and spontaneously
change their diet, becoming vegetarians or anorexic [11].
Late-onset metabolic dysfunction may appear to be spon-
taneous or associated with simple dietary changes invol-
ving a higher protein intake (change of milk, meat-based
diet). Protein hypercatabolism or the start of a treatment
(e.g. with corticosteroids or valproate) is sometimes a trig-
ger. The psychiatric symptoms that occur are nearly al-
ways accompanied by headache and/or gastrointestinal
symptoms (nausea, vomiting). Treatment based on protein
restriction allows acute decompensation to be avoided.Remethylation disorders
A feature common to remethylation disorders is defective
remethylation of homocysteine to methionine (a reaction
catalysed by methionine synthetase), usually caused by
methylene tetrahydrofolate reductase (MTHFR) deficiency
or deficiencies of cobalamin metabolism (CblC) and sub-
sequent functional deficiency of folate or B12 despite nor-
mal circulating levels.
Remethylation disorders may present at any age and
be picked up in adults in three different ways [12]:
– Systematic screening in an asymptomatic patient
where a relative is known to be affected
– Detection in the context of a haematological
problem (thrombosis in particular)
– Detection following often florid neurological
symptoms (psychiatric disorders associated with
rapid cognitive decline or even a dementia
syndrome, or motor disorders).
The psychiatric involvement may essentially be charac-
terised by psychotic symptoms (behavioural disorders,
hallucinations), which may be accompanied by disorders
of consciousness and peripheral diseases (subacute para-
plegia, peripheral neuropathy and coma). Such episodes
may even occur after the age of 50 and may be triggered
by a surgical operation. Brain imaging sometimes shows
demyelination but may be completely normal. An MRI
scan of the spinal cord may show high signal intensity in
the dorsal columns of the spinal cord similar to that seenin pernicious anaemia. Early treatment is very effective in
all cases and prevents neurological complications.
Acute intermittent porphyria
Traditionally referred to as the ‘royal malady’ as it is
popularly believed that the British king George III suf-
fered from it (something that is now disputed: Hift et al.
[13]), AIP is an autosomal dominant disease with variable
penetrance, linked to deficiency of an enzyme involved in
the biosynthesis of haem: porphobilinogen deaminase
(PBG deaminase). The prevalence is 10/100,000 in the gen-
eral population and 21/10,000 in the psychiatric hospital
population in the United States [14]. Acute attacks of por-
phyria are often triggered by porphyrinogenic treatments
(oestrogen/progesterone contraceptives, barbiturates, sul-
fonamides, antiepileptics), sepsis or alcohol ingestion [15].
The most typical manifestations are psychiatric involve-
ment, intermittent pain (especially abdominal pain) and
neurological involvement (which may even manifest as
tetraplegia and wrongly lead to the diagnosis of Guillain-
Barré syndrome).
The attacks usually begin with minor changes in behav-
iour such as anxiety, impatience or insomnia. Involvement
of the peripheral nervous system may occur early on (par-
alysis, sensory disturbances). There are sometimes noted
to be sudden changes in behaviour such as aggressiveness,
impulsivity or suicide attempts. Heightened vigilance is
required because these symptoms are sometimes under-
diagnosed or attributed to a personality disorder (e.g.
chronic fatigue, relationship difficulties). Isolated psych-
otic [16] or catatonic symptoms [15] have also been docu-
mented. The monthly occurrence during the luteal phase
in women may wrongly point towards a diagnosis of bipo-
lar disorder. Exacerbation by alcohol may resemble the
presentation of excessive alcohol intake (acute intoxica-
tion). Overall, the diagnosis of acute intermittent porphy-
ria should be considered in any psychiatric syndrome with
unexplained pain, especially if the pain is cyclical in nature
[17]. Diagnoses are achieved based on urine porphobilino-
gen measurements; urinary porphobilinogen levels are
greatly increased but may be normal between attacks.
Symptomatic treatment is based on removal of the ex-
ogenous cause (culprit drugs or alcohol) combined with
an infusion of haem arginate.
Chronic, treatable HMDs
The category of chronic, treatable HMDs includes Wilson’s
disease, Niemann-Pick disease type C (NP-C), some
remethylation disorders (homocystinuria due to cysta-
thionine beta-synthase deficiency) and cerebrotendi-
nous xanthomatosis, even though the psychiatric signs
are rarely an isolated finding in the latter. In this group
of disorders, the psychiatric manifestations usually have
a long-term course and have some special features such
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nations. In this group, neurological involvement is often
more pronounced.Wilson’s disease
Wilson’s disease is a rare genetic disease (prevalence 1/
30,000) with autosomal recessive inheritance [18]. It is
the result of mutations of the ATP7B gene on chromo-
some 13, which plays a role in copper metabolism. This
disease is characterised by a toxic build-up of copper
mainly in the liver and central nervous system. The
resulting overload is usually asymptomatic until the age
of 6, but inexorably leads to hepatic and neurological
degeneration due to the direct toxicity of copper. In most
cases, symptoms appear in preadolescent children, adoles-
cents and young adults [19]. Very rare cases have been re-
ported in subjects over the age of 60. A retrospective study
in 195 patients found psychiatric symptoms to be present
in 51% of cases and could have preceded neurological signs
in 20% of cases [20]. The major psychiatric symptoms were
behavioural disorders (irritability, aggressiveness, marked
changes in personality, disinhibition) or a depressive syn-
drome, while psychosis was found in only 1% of cases.
Differentiating the disorders from neuroleptic malignant
syndrome can sometimes be a tricky process [21]. An asso-
ciation with bipolar disorder has recently been documented
[22]. A study using the Neuropsychiatric Inventory (NPI)
allowed better characterisation of the psychiatric disorders
of patients with Wilson’s disease [23]. These psychiatric dis-
orders may be present from the very start of the disease
[24] and may remain isolated for several years [25]. Early
detection of the disease and the initiation of chelating ther-
apy or treatment with zinc salts can prevent neurological
and hepatic involvement. Treatment at the ‘psychiatric’
stage is therefore essential. The use of antipsychotics should
be avoided as far as possible (prescription limited to psych-
otic disorders or severe behavioural disorders), as they can
cause akinesia and rigidity which may progress despite
treatment with copper chelators [26].Niemann-Pick disease type C
NP-C is a lysosomal storage disease associated with an
abnormality of cellular lipid transport that results in the
accumulation of cholesterol and glycosphingolipids in the
brain and other tissues. It is due to mutations in either of
the genes, NPC1 or NPC2. The clinical spectrum of NP-C
ranges from rapidly fatal visceral forms in neonates to the
adult form—a slowly progressive neurodegenerative dis-
ease. However, it is very likely that a significant proportion
of patients is not diagnosed, or is incorrectly diagnosed,
because of the poor awareness of the disease and the rela-
tively non-specific nature of initial clinical signs [27]. In-
deed, the large range of neurological or psychiatric signsseen during the course of NP-C can mimic other neuro-
logical and psychiatric diseases.
In adult patients, a range of initial psychiatric diagnoses
have been recorded, including ‘schizophrenia’, ‘Alzheimer’s
disease in a young subject’, ‘frontotemporal dementia’,
‘Parkinson’s disease’, ‘Wilson’s disease’, ‘multiple sclerosis’,
‘Creutzfeldt-Jakob disease’ and ‘Wernicke’s encephalop-
athy’ [28]. Psychiatric disorders are the most common
presentation (38% of patients in the study by Sévin et al.
[28]). Psychiatric manifestations may remain isolated for
several years. They are usually psychotic in nature (e.g.
paranoid delusions, visual or auditory hallucinations, delu-
sions of reference, behavioural disorders with aggressive-
ness, self-mutilation, social isolation), although depressive
syndromes have been reported (e.g. isolated transient visual
hallucinations, bipolar disorder or obsessive-compulsive
disorder) [29-32]. Onset may be gradual or acute, with
spontaneous remissions and relapses. Most patients
who initially have psychotic symptoms do not have any
obvious abnormalities on neurological examination or
these abnormalities have been wrongly attributed to the
neuroleptic treatment, so much so that most patients are
diagnosed with schizophrenia or other forms of psychosis.
Alongside psychiatric disorders, patients develop early
motor signs: ataxia, abnormal movements and, an almost
consistent finding, vertical supranuclear gaze palsy. This
characteristic sign may be difficult to recognise as the con-
dition can be subtle—for a long time, only voluntary
saccadic movements are affected, whereas eye tracking
remains normal (it may be affected at a later stage). These
saccadic eye movements are studied by asking the patient
to alternately look to the sides then upwards then down-
wards on command (without the aid of the examining fin-
ger). Slowing of the movements typically starts with the
downward motion then affects the upward movements
and, eventually, the lateral movements.
The diagnosis of the disease is based on demonstration
of the accumulation of free cholesterol in fibroblasts in
culture with the help of a specific stain, filipin, and dem-
onstration of specific mutations in the genes NPC1 and
NPC2. A case where NP-C was associated with a low ce-
ruloplasmin level has recently been reported, making it
difficult to distinguish from Wilson’s disease [33].
Treatment with miglustat (Zavesca®; Actelion Pharma-
ceuticals Ltd.) reduces neuronal sphingolipid accumula-
tion and slows or delays neurological disease progression
[34,35]. Other treatments are symptomatic in nature. It
is important that the disease is detected as early as pos-
sible, especially in the more atypical adult forms [36].
Homocystinuria
Homocystinuria is a very rare autosomal recessive her-
editary disease (prevalence 1/200,000) of methionine
metabolism due to the deficiency of cystathionine beta-
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[37]. Causal mutations in this gene lead to abnormal me-
thionine metabolism, with subsequent accumulation of
homocysteine in the blood and cysteine deficiency. It is
characterised by very high plasma total homocysteine
levels (over 100 μM/L).
The vascular system, eyes and nervous system are af-
fected in the vast majority of cases. The most typical
symptoms are skeletal abnormalities with a Marfanoid
appearance, intellectual impairment, ectopia lentis and
an increased risk of thrombosis and haematological dis-
orders. Psychiatric complications are found in 51% of adult
patients [38] and include behavioural disorders (e.g. phys-
ical violence, drug or alcohol abuse), personality disorders
(hyperactivity, excessive spending and disinhibition), de-
pression and obsessive-compulsive disorder. However,
cases of psychosis or schizophrenia have been shown to be
uncommon in large cohort studies [38-40].
Laboratory investigations that need to be done if the
condition is suspected include assays of plasma total
homocysteine (increase), plasma methionine (increase)
and urinary homocystine (low). An ophthalmology exam-
ination to look for ectopia lentis is also very informative.
Cerebrotendinous xanthomatosis
Cerebrotendinous xanthomatosis is a hereditary metabolic
disorder secondary to mutations of the gene CYP27A1
(prevalence 1–9/100,000), situated on the long arm of
chromosome 2; approximately 50 mutations have been
identified to date [41]. Cerebrotendinous xanthomatosis is
characterised biochemically by sterol 27-hydroxylase defi-
ciency. This enzyme is involved in the degradation of
cholesterol. The metabolic deficiency causes gradual
build-up of cholesterol and especially its metabolite, cho-
lestanol, in various tissues including the brain and ten-
dons. Clinically, patients usually have juvenile cataract and
tendinous xanthomata associated with neurological signs
(cerebellar ataxia, spastic paraplegia and dementia) and
psychiatric disorders (psychotic manifestations, hallucina-
tions) [42]. Diagnoses are usually achieved during adult-
hood, which represents missed opportunities for early
treatment in many cases. Laboratory investigations that
should be conducted if cerebrotendinous xanthomatosis is
suspected include assay of cholestanol and, in particular,
determination of the cholesterol/cholestanol ratio (normal
<1:1,000). Treatment with chenodeoxycholic acid allows
stabilisation of, or improvement in, the psychiatric signs.
Bonnot et al. [43] reported a case of a sibship for
which an atypical psychiatric presentation associated
with polyneuropathy and pyramidal signs led to the
diagnosis of cerebrotendinous xanthomatosis. The initi-
ation of treatment with chenodeoxycholic acid resulted
in marked improvement in behaviour, leading to re-
socialisation.Chronic HMDs that are difficult to treat
Lysosomal storage diseases
Several lysosomal storage diseases may manifest them-
selves with psychiatric disorders in adults. These purely
psychiatric presentations are seen in metachromatic leu-
kodystrophy and late-onset GM2 gangliosidosis.
Metachromatic leukodystrophy is due to deficiency of
arylsulfatase A, an enzyme encoded by the gene ARSA,
giving rise to accumulation of urinary sulfatides (preva-
lence 1/50,000 to 1/170,000, autosomal recessive mode
of inheritance) [44]. It is characterised by periventricular
leukodystrophy leading to tetraparesis. The disease most
often presents in childhood (in 60% of cases) but can
occur in adults (20% of cases) and sometimes even late
in life (aged 60+ years).
In terms of genotype, late-onset forms are thought to
have different molecular bases [45]. In this case, the psychi-
atric symptoms are often present from the outset and may
mimic schizophrenia with hallucinations and behavioural
disorders [46]. The clinical presentation deteriorates after
several years, with neurological involvement (dementia,
spastic paraparesis, cerebellar ataxia, convulsive seizures),
optic nerve atrophy and a characteristic but often asymp-
tomatic demyelinating polyneuropathy. In monosympto-
matic forms, isolated polyneuropathy or initial psychiatric
disorders are present.
Two genetically distinct adult forms with different initial
presentations have been described: 1) an initially motoric
form associated with homozygous P426L mutations and
characterised by cerebellar ataxia, paraparesis and then
progressive cognitive decline with psychiatric disorders;
and 2) a form with a psychiatric onset in patients who are
heterozygous carriers of I179S mutations, during which
behavioural disorders that may mimic schizophrenia are
complemented by a dementia syndrome and motor disor-
ders (paraparesis, cerebellar syndrome) [47].
Brain MRI studies demonstrate diffuse periventricular
leukoencephalopathy. The aetiological diagnosis is based
on assay of arylsulfatase A in leucocytes. However, this
diagnostic investigation is not sufficient alone, as 1%–2%
of the population has pseudodeficiency of arylsulfatase
A. There is currently no specific treatment for this dis-
ease, but several therapeutic trials involving the use of
enzyme replacement therapy are in progress.
GM2 gangliosidosis is a sphingolipidosis associated with
hexosaminidase deficiency. GM2 gangliosidosis may
present in adulthood. Late-onset forms are sometimes
called late-onset Tay-Sachs disease, despite the fact that
minimal signs can initially appear during childhood.
GM2 gangliosidosis presents with neurological disor-
ders (peripheral motor involvement, cerebellar ataxia or
dystonia) associated with psychiatric signs in 20%–40%
of cases (e.g. acute psychotic disorder, hallucinations,
depressive syndrome) [48-50]. These signs may remain
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signs but can appear later. The occurrence of psychiatric
disorders associated with rapid cognitive decline, with ex-
ecutive and verbal deficits dominating, should alert the
physician [51]. The neurological signs are often preceded
by precursor symptoms in childhood: balance disorders,
awkwardness, difficulty in climbing stairs and recurrent
psychiatric disorders (psychotic or bipolar) [50]. Dystonia,
supranuclear gaze palsy, painful sensory polyneuropathy
and neuroautonomic disorders (hyperhidrosis) sometimes
complicate the syndrome, making the diagnosis more dif-
ficult. Brain MRI studies may be normal or demonstrate
cerebellar and cortical atrophy. Diagnoses are usually
based on measurement of the activity of hexosaminidases
A and B in leucocytes or fibroblasts. Tricyclic antidepres-
sants and phenothiazines have little efficacy and may
worsen the psychiatric signs. Miglustat has also been used
in this indication, so far without convincing results [52].
X-linked adrenoleukodystrophy
X-linked adrenoleukodystrophy (X-ALD) is a rare gen-
etic disease affecting peroxisomal metabolism of very
long chain fatty acids (VLCFAs) due to mutations in the
gene ABCD1 located on Xq28. The incidence of X-ALD
is approximately 1/17,000 births, making it the com-
monest of the peroxisomal disorders [53].
The classic cerebral form of X-ALD presents in child-
hood with progressive demyelination of the peripheral and
central nervous system, adrenal insufficiency and accumu-
lation of VLCFAs in the plasma and tissues; 30%–40% of
affected males and over half of carrier females may de-
velop adrenomyeloneuropathy in adulthood, characterised
by progressive spastic paraplegia [54]. The majority of
affected adult patients described to date had psychiatric
signs that preceded motor signs by many years [55]. TheFigure 1 Systematic screening in psychotic disorders. ALP alkaline pho
imaging, EEG electroencephalography, ECG echocardiography.psychiatric signs present as gradual changes in behaviour,
mania, depression and acute psychotic episodes [56,57].
Creatine deficiency syndromes
Creatine deficiency syndromes are characterised by intrace-
rebral creatine deficiency due to deficiencies of creatine
synthesis (deficiency of AGT or GAMT) and of the creatine
transporter (SLC6A8 deficiency). The transporter deficiency
makes the disease very difficult to treat. These diseases fea-
ture severe intellectual impairment, with severe language
delay, which may be variously accompanied by epilepsy, an
extrapyramidal syndrome and behavioural disorders. Most
of the time, they are detected in children, but adult forms
have been documented. Carriers of mutations of the crea-
tine transporter gene (SLCA8) may have mild intellectual
impairment and behavioural disorders (mainly aggressive-
ness) [58]. Their diagnosis is possible by measurement of
creatine and guanidinoacetate in biological fluids.
How can screening be done?
Screening for HMDs in a population of individuals with
mental disorders is most complex when the disorder oc-
curs in an isolated manner in a patient with no personal
or family history of a metabolic disorder. Moreover, the
presence of minor neurological signs in patients with
mental disorders can complicate the detection of some-
thing that may be of metabolic origin. Yet, it is at this
stage that the diagnosis and resulting management can
completely change the patient’s course and a systematic
screening can be proposed (Figure 1).
Should systematic screening be offered? This does not
appear feasible, particularly as the laboratory investiga-
tions traditionally suggested for screening for HMDs may
be ineffective (neither sensitive nor specific) in a popula-
tion of individuals with psychiatric disorders (personalsphatase, TSH thyroid stimulating hormone, MRI magnetic resonance
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fluence of numerous confounding factors: psychotropic
treatments, extremely sedentary lifestyle, disordered diet,
use of toxic substances, etc. Resistance to treatment and
even worsening of the disorders should also serve as an
alarm signal. If atypical symptoms are present, a simple
diagnostic algorithm should comprise the following: first-
rank symptoms (visual hallucinations, mental confusion,
catatonia, fluctuation of symptoms, unusual (or paradox-
ical) response to treatment, progressive cognitive change)
associated with second-rank symptoms (early onset, acute
onset, intellectual impairment, lack of treatment efficacy)
which may aid the psychiatrist in detecting an HMD [59].
Screening for these diseases is therefore very specific
and requires specialist advice (Figure 2). However, hav-
ing said that, it is important to alert psychiatrists and
general practitioners to think about these conditions. In
current practice, the management of psychotic disorders
must always be accompanied by a specific work-up.
Conclusion
Unfortunately, not all patients with an HMD benefit
from a diagnosis or specific treatment in the psychiatricFigure 2 Algorithm for the diagnosis of hereditary metabolic disorde
HVA homovanillic acid, MR magnetic resonance, SHIAA 5-hydroxyindoleacetsetting despite the fact that there are referral centres
specialising in these conditions. This shortcoming may
partly be explained by the complexity of these diagnoses
and the fact that they are rare. The psychiatric signs that
suggest these disorders are usually non-specific, and it is
the general physical context that points towards the cor-
rect diagnosis.
Considerable work remains to be done to describe these
disorders since knowledge about the presentation of these
diseases in adults has not yet been clearly documented.
Every day, new case reports are described that all have
special features and variable modes of presentation.
The metabolic approach to diagnosing mental disorders
is a fast-expanding area and, in years to come, will prob-
ably alter the diagnostic process in psychiatry. However,
the very history of psychiatry, where for many years those
involved in treatment called for a non-medical model,
making the traditional distinction between treatments for
the mind and physical medicine, also partly explains the
lack of knowledge in this field. It is now essential that ge-
neticists and neurologists on the one hand and psychiatrists
on the other are able to collaborate in the management of
adult patients.rs in the presence of atypical symptoms. CSF cerebrospinal fluid,
ic acid.
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